Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kiora Pharmaceuticals Inc (KPRX) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kiora Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1372514.
Total stock buying since 2015: $9,928,337.
Total stock sales since 2015: $16,456,172.
Total stock option exercises since 2015: $69,484.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 22,291 | $95,203 | 0 | $0 | 0 | $0 |
| 2021 | 1,548,954 | $4,025,938 | 3,414,101 | $16,080,422 | 0 | $0 |
| 2020 | 23,000 | $70,230 | 0 | $0 | 0 | $0 |
| 2019 | 1,154,648 | $1,033,258 | 209,329 | $70,770 | 0 | $0 |
| 2018 | 14,208,551 | $1,791,836 | 0 | $0 | 0 | $0 |
| 2017 | 102,500 | $22,875 | 13,338 | $39,143 | 18,653 | $13,261 |
| 2016 | 15,000 | $22,335 | 83,939 | $265,837 | 86,765 | $56,223 |
| 2015 | 477,777 | $2,866,662 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-09 | 4,250 | $15,400 | 0 | $0 | 0 | $0 |
| 2024-08 | 8,250 | $31,045 | 0 | $0 | 0 | $0 |
| 2024-06 | 9,791 | $48,758 | 0 | $0 | 0 | $0 |
| 2021-11 | 17,853 | $25,172 | 0 | $0 | 0 | $0 |
| 2021-08 | 0 | $0 | 192,775 | $463,045 | 0 | $0 |
| 2021-07 | 0 | $0 | 3,221,326 | $15,617,377 | 0 | $0 |
| 2021-01 | 1,531,101 | $4,000,766 | 0 | $0 | 0 | $0 |
| 2020-02 | 23,000 | $70,230 | 0 | $0 | 0 | $0 |
| 2019-12 | 0 | $0 | 1,961 | $13,589 | 0 | $0 |
| 2019-11 | 0 | $0 | 2,001 | $8,584 | 0 | $0 |
| 2019-09 | 605,001 | $945,651 | 0 | $0 | 0 | $0 |
| 2019-07 | 0 | $0 | 205,367 | $48,597 | 0 | $0 |
| 2019-03 | 549,647 | $87,607 | 0 | $0 | 0 | $0 |
| 2018-12 | 100,353 | $13,532 | 0 | $0 | 0 | $0 |
| 2018-11 | 360,000 | $54,226 | 0 | $0 | 0 | $0 |
| 2018-05 | 390,000 | $65,696 | 0 | $0 | 0 | $0 |
| 2018-04 | 13,358,198 | $1,658,382 | 0 | $0 | 0 | $0 |
| 2017-08 | 22,500 | $22,875 | 0 | $0 | 0 | $0 |
| 2017-06 | 80,000 | $0 | 0 | $0 | 17,570 | $11,420 |
| 2017-03 | 0 | $0 | 13,338 | $39,143 | 0 | $0 |
| 2017-02 | 0 | $0 | 0 | $0 | 1,083 | $1,841 |
| 2016-09 | 15,000 | $22,335 | 0 | $0 | 0 | $0 |
| 2016-06 | 0 | $0 | 83,939 | $265,837 | 86,765 | $56,223 |
| 2015-02 | 477,777 | $2,866,662 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-09-11 | Stengone Carmine N. (Director) | Buy | 1,250 | 3.68 | 4,600 |
| 2024-09-10 | Shapiro Aron (Director) | Buy | 3,000 | 3.60 | 10,800 |
| 2024-08-19 | Walters-hoffert Lisa (Director) | Buy | 1,250 | 3.86 | 4,825 |
| 2024-08-19 | Tyle Praveen (Director) | Buy | 5,000 | 3.96 | 19,800 |
| 2024-08-14 | Tosca Melissa (CFO) | Buy | 2,000 | 3.21 | 6,420 |
| 2024-06-14 | Tosca Melissa (EVP Finance) | Buy | 100 | 5.25 | 525 |
| 2024-06-14 | Daniels Eric Joseph (Chief Development Officer) | Buy | 1,431 | 5.29 | 7,569 |
| 2024-06-13 | Parsons Erin (Director) | Buy | 5,260 | 4.88 | 25,668 |
| 2024-06-13 | Strem Brian M. (President and CEO) | Buy | 3,000 | 5.00 | 14,996 |
| 2021-11-18 | Strem Brian M. (President and CEO) | Buy | 17,853 | 1.41 | 25,172 |
| 2021-08-02 | Boyd Steven | Sale | 192,775 | 2.40 | 463,045 |
| 2021-07-30 | Boyd Steven | Sale | 68,188 | 2.69 | 183,562 |
| 2021-07-29 | Boyd Steven (Director) | Sale | 400,000 | 3.00 | 1,200,000 |
| 2021-07-28 | Boyd Steven (Director) | Sale | 375,443 | 3.28 | 1,232,579 |
| 2021-07-27 | Boyd Steven (Director) | Sale | 2,377,695 | 5.47 | 13,001,236 |
| 2021-01-06 | Boyd Steven | Buy | 1,531,101 | 2.61 | 4,000,766 |
| 2020-02-10 | Boyd Steven | Buy | 12,000 | 3.02 | 36,240 |
| 2020-02-06 | Boyd Steven | Buy | 11,000 | 3.09 | 33,990 |
| 2019-12-06 | Goldberg Morton | Sale | 1,961 | 6.93 | 13,589 |
| 2019-11-12 | Goldberg Morton | Sale | 2,001 | 4.29 | 8,584 |
| 2019-09-30 | Boyd Steven | Buy | 5,001 | 1.57 | 7,851 |
| 2019-09-29 | Boyd Steven | Buy | 600,000 | 1.56 | 937,800 |
| 2019-07-15 | Romano Sarah (Chief Financial Officer) | Sale | 6,584 | .23 | 1,534 |
| 2019-07-15 | Wirostko Barbara (Chief Medical Officer) | Sale | 6,488 | .23 | 1,511 |
| 2019-07-15 | Mann Brenda (VP of Research & Development) | Sale | 6,350 | .23 | 1,479 |
| 2019-07-15 | Manzo Michael P. (VP of Engineering) | Sale | 6,584 | .23 | 1,534 |
| 2019-07-15 | From Stephen (President and CEO) | Sale | 42,452 | .23 | 9,891 |
| 2019-07-12 | Romano Sarah (Chief Financial Officer) | Sale | 6,583 | .24 | 1,553 |
| 2019-07-12 | Wirostko Barbara (Chief Medical Officer) | Sale | 6,488 | .24 | 1,531 |
| 2019-07-12 | Mann Brenda (VP of Research & Development) | Sale | 6,350 | .24 | 1,498 |
| 2019-07-12 | Manzo Michael P. (VP of Engineering) | Sale | 6,583 | .24 | 1,553 |
| 2019-07-12 | From Stephen (President and CEO) | Sale | 42,452 | .24 | 10,018 |
| 2019-07-11 | Romano Sarah (Chief Financial Officer) | Sale | 6,583 | .24 | 1,586 |
| 2019-07-11 | Wirostko Barbara (Chief Medical Officer) | Sale | 6,487 | .24 | 1,563 |
| 2019-07-11 | Mann Brenda (VP of Research & Development) | Sale | 6,349 | .24 | 1,530 |
| 2019-07-11 | Manzo Michael P. (VP of Engineering) | Sale | 6,583 | .24 | 1,586 |
| 2019-07-11 | From Stephen (President and CEO) | Sale | 42,451 | .24 | 10,230 |
| 2019-03-29 | Boyd Steven | Buy | 298,189 | .15 | 46,219 |
| 2019-03-28 | Boyd Steven | Buy | 130,811 | .15 | 20,275 |
| 2019-03-27 | Boyd Steven | Buy | 120,647 | .17 | 21,113 |
| 2018-12-11 | Boyd Steven | Buy | 30,953 | .14 | 4,302 |
| 2018-12-10 | Boyd Steven | Buy | 69,400 | .13 | 9,230 |
| 2018-11-16 | Boyd Steven | Buy | 178,136 | .16 | 27,967 |
| 2018-11-15 | Boyd Steven | Buy | 126,735 | .14 | 18,376 |
| 2018-11-14 | Boyd Steven | Buy | 55,129 | .14 | 7,883 |
| 2018-05-29 | Boyd Steven | Buy | 40,700 | .19 | 7,773 |
| 2018-05-25 | Boyd Steven | Buy | 17,575 | .19 | 3,374 |
| 2018-05-18 | Boyd Steven | Buy | 1,725 | .18 | 319 |
| 2018-05-14 | Boyd Steven | Buy | 15,758 | .18 | 2,804 |
| 2018-05-11 | Boyd Steven | Buy | 49,142 | .18 | 8,796 |
| 2018-05-10 | Boyd Steven | Buy | 23,917 | .18 | 4,328 |
| 2018-05-09 | Boyd Steven | Buy | 103,953 | .17 | 17,152 |
| 2018-05-08 | Boyd Steven | Buy | 37,230 | .16 | 5,994 |
| 2018-05-07 | Boyd Steven | Buy | 14,252 | .16 | 2,294 |
| 2018-05-04 | Boyd Steven | Buy | 85,748 | .15 | 12,862 |
| 2018-04-20 | Boyd Steven | Buy | 496,304 | .18 | 87,349 |
| 2018-04-19 | Boyd Steven | Buy | 1,256,920 | .16 | 199,850 |
| 2018-04-18 | Boyd Steven | Buy | 781,254 | .16 | 123,438 |
| 2018-04-17 | Garanzini Michael (Chief Commercial Officer) | Buy | 156,250 | .00 | 0 |
| 2018-04-17 | Boyd Steven | Buy | 1,895,610 | .15 | 278,654 |
| 2018-04-17 | Romano Sarah (Chief Financial Officer) | Buy | 62,500 | .00 | 0 |
| 2018-04-17 | From Stephen (President and CEO) | Buy | 125,000 | .00 | 0 |
| 2018-04-16 | Boyd Steven | Buy | 1,159,167 | .12 | 144,895 |
| 2018-04-13 | Boyd Steven | Buy | 7,425,193 | .11 | 824,196 |
| 2017-08-15 | Romano Sarah (Interim CFO) | Buy | 10,000 | 1.00 | 10,000 |
| 2017-08-10 | From Stephen (President and CEO) | Buy | 12,500 | 1.03 | 12,875 |
| 2017-06-14 | Romano Sarah (Interim CFO) | Buy | 20,000 | .00 | 0 |
| 2017-06-14 | From Stephen (President and CEO) | Buy | 60,000 | .00 | 0 |
| 2017-06-02 | Chaney Paul G | Option Ex | 17,570 | .65 | 11,420 |
| 2017-03-13 | Ventech Capital Ii | Sale | 4,419 | 2.80 | 12,386 |
| 2017-03-06 | Goldberg Morton | Sale | 8,919 | 3.00 | 26,757 |
| 2017-02-27 | Goldberg Morton | Option Ex | 1,083 | 1.70 | 1,841 |
| 2016-09-15 | From Stephen (President and CEO) | Buy | 15,000 | 1.49 | 22,335 |
| 2016-06-30 | From Stephen (President and CEO) | Option Ex | 52,990 | .65 | 34,337 |
| 2016-06-15 | Goldberg Morton | Sale | 15,000 | 3.16 | 47,355 |
| 2016-06-10 | Ventech Capital Ii | Sale | 15,433 | 3.00 | 46,329 |
| 2016-06-09 | Ventech Capital Ii | Sale | 13,167 | 3.08 | 40,528 |
| 2016-06-08 | Ventech Capital Ii | Sale | 2,400 | 3.20 | 7,680 |
| 2016-06-07 | Goldberg Morton | Sale | 746 | 3.31 | 2,472 |
| 2016-06-07 | Ventech Capital Ii | Sale | 17,000 | 3.24 | 55,063 |
| 2016-06-06 | Goldberg Morton | Sale | 5,543 | 3.25 | 18,042 |
| 2016-06-06 | Ventech Capital Ii | Sale | 10,000 | 3.27 | 32,679 |
| 2016-06-03 | Goldberg Morton | Sale | 4,650 | 3.37 | 15,689 |
| 2016-06-03 | Goldberg Morton | Option Ex | 33,775 | .65 | 21,886 |
| 2015-02-19 | Ipsa (innoven Partenaires S.a.) | Buy | 366,667 | 6.00 | 2,200,002 |
| 2015-02-19 | Ventech Capital Ii | Buy | 102,777 | 6.00 | 616,662 |
| 2015-02-19 | Chaney Paul G | Buy | 8,333 | 6.00 | 49,998 |
Insider trading activities including stock purchases, stock sales, and option exercises of KPRX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kiora Pharmaceuticals Inc (symbol KPRX, CIK number 1372514) see the Securities and Exchange Commission (SEC) website.